3-(4-Methylsulphonylphenyl)-4-phenyl-5-trifluoromethylisoxazole manufacturers
- CAY10404
-
- $34.00
-
2026-07-27
- CAS:340267-36-9
- Purity: 99.85%
- Supply Ability: 10g
|
| | 3-(4-Methylsulphonylphenyl)-4-phenyl-5-trifluoromethylisoxazole Basic information |
| Product Name: | 3-(4-Methylsulphonylphenyl)-4-phenyl-5-trifluoromethylisoxazole | | Synonyms: | 3-(4-methylsulfonylphenyl)-4-phenyl-5-(trifluoromethyl)-1,2-oxazole;CAY10404;Isoxazole, 3-[4-(methylsulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)-;3-(4-METHYLSULPHONYLPHENYL)-4-PHENYL-5-T;Bcl-XL,CAY10404,cancer,COX,anti-inflammatory,Bcl-2,Apoptosis,Akt,H-1703,Cyclooxygenase,NSCLC,CAY 10404,H-358,inhibit,cell,pGSK-3β,H-460,analgesic,MAPK,CAY-10404,cyclooxygenase-2,lung,anti-cancer,Inhibitor,Non-small,Protein kinase B,pAkt,PKB;CAY10404, 10 mM in DMSO;3-(4-Methylsulphonylphenyl)-4-phenyl-5-trifluoromethylisoxazole | | CAS: | 340267-36-9 | | MF: | C17H12F3NO3S | | MW: | 367.34 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | 3-(4-Methylsulphonylphenyl)-4-phenyl-5-trifluoromethylisoxazole Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:100.0(Max Conc. mg/mL);272.23(Max Conc. mM) | | form | A crystalline solid | | color | White to off-white |
| | 3-(4-Methylsulphonylphenyl)-4-phenyl-5-trifluoromethylisoxazole Usage And Synthesis |
| Uses | CAY10404 is a potent and selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 1 nM and a selectivity index (SI; COX-1 IC50/COX-2 IC50) of >500000. CAY10404 is a potent PKB/Akt and MAPK signaling pathways inhibitor and induces apoptosis in non-small cell lung cancer (NSCLC) cells. CAY10404, a diarylisoxazole, has good analgesic, anti-inflammatory, and anti-cancer activities[1][2][3]. | | Definition | ChEBI: Isoxazole, 3-[4-(methylsulfonyl)phenyl]-4-phenyl-5-(trifluoromethyl)- is a sulfonic acid derivative. | | in vivo | CAY10404 (50 mg/kg/day; ip; for 4 days) decreases lung inflammation in HTV mice and attenuates ventilator-induced lung injury[2].
| Animal Model: | Adult male C57Bl/6J mice weighing 24-30 g[2] | | Dosage: | 50 mg/kg | | Administration: | IP; daily; for 4 days | | Result: | Attenuated cyclooxygenase activity, significantly decreasing BAL PGE2 and 6-keto PGF1α.
Decreased lung inflammation in HTV mice (high tidal volume; 20 ml/kg; for 4 hours) and attenuates ventilator-induced lung injury.
|
| | IC 50 | COX-2: 1 nM (IC50); COX-1: >500 μM (IC50) | | References | [1] A G Habeeb, et al. Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity. J Med Chem. 2001 Aug 30;44(18):2921-7. DOI:10.1021/jm0101287
[2] Joshua A Robertson, et al. The role of cyclooxygenase-2 in mechanical ventilation-induced lung injury. Am J Respir Cell Mol Biol. 2012 Sep;47(3):387-94. DOI:10.1165/rcmb.2011-0005OC
[3] Yongseon Cho, et al. Effects of CAY10404 on the PKB/Akt and MAPK pathway and apoptosis in non-small cell lung cancer cells. Respirology. 2009 Aug;14(6):850-8. DOI:10.1111/j.1440-1843.2009.01563.x |
| | 3-(4-Methylsulphonylphenyl)-4-phenyl-5-trifluoromethylisoxazole Preparation Products And Raw materials |
|